Lilly CEO to pharma: Stop talking and get going on pricing by Eric Sagonowsky Wednesday, January 10, 2018 Merck & Co.'s top executive said Monday that pricing pressure isn't likely to get worse. But Eli Lilly CEO David Ricks begs to differ.
Senator blasts 'revolving door' in Washington at Azar hearing by Eric Sagonowsky Wednesday, November 29, 2017 Drug prices took center stage at a contentious confirmation hearing for former Eli Lilly executive Alex Azar, who's up for the top job at HHS.
FDA warns of potentially fatal skin reactions to Lilly's Zyprexa by Emily Wasserman Wednesday, May 11, 2016 The FDA is warning about potentially fatal skin reactions tied to Eli Lilly’s antipsychotic Zyprexa (olanzapine). The news deals some unfavorable cards to Lilly as it competes in a crowded long-acting injectables market.
FDA nixes long-acting Zyprexa by admin Thursday, February 28, 2008 Who at the FDA really cares what those advisory committees think? The FDA has
